Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVF-002 (Karolinska Institutet)
- Development stage
- Preclinical
- Lead developer
- SVF Vaccines
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
SVF-002 is an investigational DNA-based vaccine candidate designed to prevent respiratory syncytial virus (RSV) infection. Developed by researchers at the Karolinska Institutet and its spin-off, Svenska Vaccinfabriken (SVF), the vaccine utilizes a DNA plasmid platform to deliver genetic sequences encoding key RSV antigens, typically including the fusion (F), attachment (G), and nucleoprotein (N) proteins. The goal of this multi-antigen approach is to elicit both robust neutralizing antibody responses and broad T-cell mediated immunity, potentially offering more comprehensive protection than single-antigen vaccines. SVF-002 is often administered using needle-free delivery technologies or electroporation to enhance cellular uptake of the DNA plasmids. It is primarily being developed for the prevention of RSV-related lower respiratory tract disease in vulnerable populations, including infants and the elderly.
- Other names
- respiratory syncytial virus vaccinesRSV-DNA vaccineKarolinska RSV DNA vaccinerespiratory syncytial virus DNA vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)RSV G (Respiratory syncytial virus attachment glycoprotein)RSV N (Respiratory syncytial virus nucleoprotein)
Beyond the preview
Go deeper on SVF-002 (Karolinska Institutet).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SVF-002 (Karolinska Institutet).